NantCell received the funding at a $4bn valuation, giving existing investor Celgene a 2.8% stake in the cancer immunotherapy developer.

Novartis returned to reinvest in digital medicine developer Pear Therapeutics as part of a Temasek-led round that took its overall funding to more than $134m.

The series A funding will help UMass-founded genetic disease therapy developer Apic Bio progress targeted drugs for ALS and Alpha-1 antitrypsin deficiency.

Celgene and Evotec both invested in Exscientia, as the automated drug discovery services provider added Roche to its roster of development partners.

Biontech, a spinout of Johannes Gutenberg University Mainz, has received $91.5m in funding as part of the extension of a deal to develop a cancer immunotherapy candidate with Sanofi.

University of Chicago’s Polsky Center for Entrepreneurship has formed microbiome-focused Avnovum Therapeutics, BiomeSense, Covira and Oxalo Therapeutics over the past year.

Spun out of Tübingen, Justus Liebig University Gießen and Münster, Atriva Therapeutics has raised an initial $1.4m to progress next-generation antiviral drugs for conditions including influenza.

Schrödinger raised $85m from investors including WuXi AppTec and GV and will use the money to expand the capabilities of its drug discovery software.

Ping An, Samsung, CLP, Tasly and Health 100 have all taken part in a series C round for the diabetes management technology provider.

Biontech has received $91.5m in equity funding as part of the extension of a deal to develop a cancer immunotherapy candidate with Sanofi.